Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Prostate cancer

Prostate cancer non-coding RNA 1 (PRNCR1); prostate-specific transcript 1 (PCGEM1)

In vitro, cell culture and mouse studies suggest inhibiting the long noncoding RNAs (lncRNAs) PRNCR1 or PCGEM1 could help treat prostate cancer. Chromatin isolation by RNA purification and in vitro binding studies showed that the lncRNAs PRNCR1 and PCGEM1 bound directly to androgen receptor (AR) and associated with AR-regulated genes in a prostate cancer cell line. In this cell line, small hairpin RNA knockdown of either lncRNA decreased AR signaling compared with no knockdown. In a mouse xenograft model of prostate cancer, shRNA against either lncRNA decreased tumor growth compared with control shRNA. Next steps include additional studies on the expression of PRNCR1 and PCGEM1 in prostate cancer patient samples (see IncRNA meets the androgen receptor, page 4).

SciBX 6(34); doi:10.1038/scibx.2013.926
Published online Sept. 5, 2013

Unpatented; licensing status not applicable

Yang, L. et al. Nature;
published online Aug. 14, 2013;
doi:10.1038/nature12451
Contact: Michael G. Rosenfeld, University of California, San Diego, La Jolla, Calif.
e-mail:
mrosenfeld@ucsd.edu
Contact: Chunru Lin, The University of Texas MD Anderson Cancer Center, Houston, Texas
e-mail:
clin2@mdanderson.org
Contact: Liuqing Yang,
same affiliation as above
e-mail:
lyang7@mdanderson.org